{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:37:04Z","timestamp":1775515024126,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"CONACyT","award":["MOD-ORD-18-2014"],"award-info":[{"award-number":["MOD-ORD-18-2014"]}]},{"name":"CONACyT","award":["PCI-006-06-14"],"award-info":[{"award-number":["PCI-006-06-14"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jsbmb.2014.12.006","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T18:07:51Z","timestamp":1418407671000},"page":"122-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells"],"prefix":"10.1016","volume":"148","author":[{"given":"Mariana","family":"Segovia-Mendoza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Elena","family":"Gonz\u00e1lez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isela","family":"Mart\u00ednez-Reza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Garc\u00eda-Quiroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heriberto","family":"Prado-Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Ibarra-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Esparza-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Larrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-0508","authenticated-orcid":false,"given":"Roc\u00edo","family":"Garc\u00eda-Becerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2014.12.006_bib0005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"Suppl. 37","key":"10.1016\/j.jsbmb.2014.12.006_bib0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0959-8049(01)00230-1","article-title":"The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities","volume":"4","author":"Yarden","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0015","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine","volume":"14","author":"Ross","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0020","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"Baselga","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0025","doi-asserted-by":"crossref","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","article-title":"A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy","volume":"68","author":"Lee-Hoeflich","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0030","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2 the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0022-4731(89)90072-1","article-title":"Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu","volume":"34","author":"Harris","year":"1989","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0002-9610(05)80897-9","article-title":"Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients","volume":"164","author":"Osaki","year":"1992","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0045","first-page":"217","article-title":"Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes","volume":"10","author":"Harlozinska","year":"1996","journal-title":"In Vivo"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0050","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0055","first-page":"1274","article-title":"ZD1839 a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR\/HER2 and EGFR\/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells","volume":"9","author":"Anido","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.10411","article-title":"Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (\u2018Iressa\u2019) is independent of EGFR expression level","volume":"198","author":"Campiglio","year":"2004","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0065","first-page":"8887","article-title":"Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2\/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo","volume":"61","author":"Moulder","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0070","first-page":"7184","article-title":"The tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells","volume":"61","author":"Moasser","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0075","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-07-0507","article-title":"The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells","volume":"6","author":"Krol","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0080","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D in reducing cancer risk and progression","volume":"14","author":"Feldman","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1017\/S1368980099000385","article-title":"Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk","volume":"2","author":"Janowsky","year":"1999","journal-title":"Public Health Nutr."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0090","first-page":"118","article-title":"Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases","volume":"82","author":"Mawer","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0095","first-page":"239","article-title":"Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis","volume":"51","author":"Berger","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0100","first-page":"4848","article-title":"Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53","volume":"59","author":"Mathiasen","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0960-0760(96)00055-6","article-title":"1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells","volume":"58","author":"Simboli-Campbell","year":"1996","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-3-642-55580-0_6","article-title":"Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells","volume":"164","author":"Lowe","year":"2003","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0115","doi-asserted-by":"crossref","first-page":"e45063","DOI":"10.1371\/journal.pone.0045063","article-title":"Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy","volume":"7","author":"Garcia-Quiroz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/1471-2407-14-230","article-title":"Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: a potential new therapeutic approach","volume":"14","author":"Santos-Martinez","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0125","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0169-6009(90)90023-9","article-title":"The mechanisms of vitamin D toxicity","volume":"11","author":"Vieth","year":"1990","journal-title":"Bone Miner."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0130","first-page":"2734","article-title":"Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells","volume":"48","author":"Koga","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mce.2011.02.023","article-title":"The coupling of epidermal growth factor receptor down regulation by 1alpha, 25-dihydroxyvitamin D3 to the hormone-induced cell cycle arrest at the G1-S checkpoint in ovarian cancer cells","volume":"338","author":"Shen","year":"2011","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0140","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00432-013-1476-3","article-title":"Doxorubicin induces atypical NF-kappaB activation through c-Abl kinase activity in breast cancer cells","volume":"139","author":"Esparza-Lopez","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0150","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nrc2196","article-title":"Vitamin D signalling pathways in cancer: potential for anticancer therapeutics","volume":"7","author":"Deeb","year":"2007","journal-title":"Nat. Rev. Cancer."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PPO.0b013e3181c51ee6","article-title":"Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy","volume":"16","author":"Trump","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0160","first-page":"3371","article-title":"1alpha, 25-dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells","volume":"6","author":"Swami","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/jca.1.101","article-title":"Vitamin D in combination cancer treatment","volume":"1","author":"Ma","year":"2010","journal-title":"J. Cancer"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0170","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1158\/1078-0432.CCR-06-1165","article-title":"A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors","volume":"13","author":"Fakih","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0175","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00280-009-1000-2","article-title":"A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors","volume":"65","author":"Muindi","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0180","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0185","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1078-1439(03)00170-4","article-title":"Development of weekly high-dose calcitriol based therapy for prostate cancer","volume":"21","author":"Beer","year":"2003","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1677\/jme.1.01813","article-title":"Identification and characterization of a response element in the EGFR promoter that mediates transcriptional repression by 1,25-dihydroxyvitamin D3 in breast cancer cells","volume":"35","author":"McGaffin","year":"2005","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0195","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1007\/s10637-013-0030-0","article-title":"Dual inhibition of MEK1\/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation","volume":"31","author":"Song","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0200","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1371\/journal.pmed.0040316","article-title":"Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics","volume":"4","author":"Cragg","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.jsbmb.2014.12.006_bib0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1005772432465","article-title":"Comparative effects of 1,25(OH) 2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells","volume":"42","author":"Simboli-Campbell","year":"1997","journal-title":"Breast Cancer Res. Treat."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076014003124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076014003124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:48:58Z","timestamp":1760744938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076014003124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":41,"alternative-id":["S0960076014003124"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2014.12.006","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2014.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}